Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Dudley W. Lamming, … , David M. Sabatini, Joseph A. Baur
Dudley W. Lamming, … , David M. Sabatini, Joseph A. Baur
Published March 1, 2013
Citation Information: J Clin Invest. 2013;123(3):980-989. https://doi.org/10.1172/JCI64099.
View: Text | PDF
Review Series

Rapalogs and mTOR inhibitors as anti-aging therapeutics

  • Text
  • PDF
Abstract

Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.

Authors

Dudley W. Lamming, Lan Ye, David M. Sabatini, Joseph A. Baur

×

Figure 1

mTOR signaling.

Options: View larger image (or click on image) Download as PowerPoint
mTOR signaling.
mTOR is found in two complexes, mTORC1 and mTORC2. mTORC...
mTOR is found in two complexes, mTORC1 and mTORC2. mTORC1 is regulated in part via the TSC complex, which normally act as a GTPase-activating protein for Rheb to suppress mTORC1 signaling. mTORC1 is also regulated by amino acids via the Ras-related GTP binding (Rag) family of small GTPases. The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110). mTORC1 promotes growth by enhancing ribosomal biogenesis, translation, and other anabolic processes, while inhibiting autophagy. mTORC1 suppresses insulin/IGF-1 signaling via direct regulation of Grb10 and S6K, which subsequently reduces signaling to mTORC2. AKT, an inhibitor of TSC1/2, is one of several direct substrates of mTORC2. Processes that are upregulated by mTOR signaling are shown in red; those that are downregulated by mTOR signaling are shown in blue.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts